A Look At Bio Rad Laboratories (BIO) Valuation After Recent Share Price Weakness

Bio-Rad Laboratories (BIO) has drawn fresh attention after recent trading left the stock with a one-month return of about a 10% decline and a past three-month return near a 19% decline, prompting closer scrutiny from investors.

See our latest analysis for Bio-Rad Laboratories.

The recent 1-day share price return of a 1.12% decline and 30-day share price return of a 9.55% decline, alongside a 1-year total shareholder return of a 4.25% decline and a 5-year total shareholder return of a 55.09% decline, points to fading momentum as investors reassess Bio-Rad Laboratories at a share price of $268.25.

If these moves have you reconsidering your watchlist, it could be a good moment to broaden your search with our curated collection of 27 healthcare AI stocks.

With Bio Rad showing an intrinsic discount of about 36% and trading roughly 21% below the current analyst price target, you have to ask: is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 22.9% Undervalued

Against a last close of $268.25, the widely followed narrative pegs Bio-Rad Laboratories' fair value at about $348, creating a clear valuation gap investors are trying to make sense of.

Resilience and stable growth in consumables and reagents, demonstrated by high single-digit growth, especially in the face of delayed academic and instrument funding, are shifting Bio-Rad's sales mix toward higher-margin, recurring revenues, supporting overall profitability and cash flow stability.

Read the complete narrative.

Want to see what kind of revenue curve and profit margins sit behind that valuation gap? The narrative leans heavily on recurring consumables strength, cautious earnings expectations, and a much richer future earnings multiple than the sector norm.

Result: Fair Value of $348 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on instrument demand and on China remaining supportive, and ongoing margin pressure from higher material costs or weaker high margin products could quickly undercut that optimism.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Next Steps

If this mix of concerns and optimism feels finely balanced, now is a good time to look through the details yourself and weigh the trade off of 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

Do not stop your research with one company. Broaden your options now with a few focused stock ideas that could suit very different investing styles.

• Target value by scanning companies that appear priced below what their fundamentals suggest using our list of 56 high quality undervalued stocks.
• Prioritise resilience by reviewing 80 resilient stocks with low risk scores that may offer a smoother ride when markets turn choppy.
• Hunt for future standouts before they are widely followed with a curated screener containing 23 high quality undiscovered gems that many investors have not yet considered.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com